www.***.com
70
#"$ !
!
$
%$Q
N
#*92/88JJ>H,**36.6L,*BEKN96+
N
(N&PO,*
(*(
$Q
N
?<BM-20R30,**4JJ/4JJ,
!",')
#Q
D;<*1500/JJ3,*A;<*270/JJ3,
>FN8.0H/GI,*>K*24.8+N@IK*15/JJ3,
Q@C*91*,:@CC*30.5*,=FH*335*JH/GI
CT(10
"!'%) ($#&/.,*
-,+
-,+
-,+
,+
MRI(
4
CT
!#"
()(
'&
"#
%
$
!
#
"!$
&
!%
#%
#
$()
*" &"!!!
++")'!
!
&
%
"$#
!$#
NIH..
+-/0
'
+$#" "$
(
+ "
)+ "&! +-/0
'13785
+$#"$#"
(
+#" "
)624+%!#
*,.
"$
B-4C82uy
"#>.wo}H:'l:<rtPAxM=$
)+5@x?EQ€YY\c\bRWaf^ca\e^RXa`b`]\aR[d`\ax;
,~FzljG!%uvsq
qrnj6xLy
7
D(jPAB~
pJo}mu
^_SRX[hZXWOxUTVx^\dagRX[Re`_b
B#>.~n{okxt18NG!
rt-PAM382iG/18&Ii)+>89K€0|‚200510*
t-PA(31-2
$D6?9:>A8
&'#' +3.!+4
B3*C
3/05"'4)B
6*C
%
<A=;A7,,,[email protected]
8-1=CT9
)A@,8*2<A
CT5:99;@8?>4+=
31570
9
(/ #"!&'%$
6
99.5/=BB
)('#
*( #
"#
'
+(%&$#
MELT Japan!www.melt.umin.ac.JP
3=:6;569<6421<879
#*+(,)-
"'&
/. #
%&
0.$!
Flacke S et al. Middle cerebral artery (MCA) susceptibility sign at susceptibility-based perfusion MR imaging: clinical
importance and comparison with hyperdense MCA sign at CT. Radiology 2000;215:476–482
&
K/2AN(TSR !
/2PF'O*A%
WXVA-.+K#EJ?R)PQH
M?=<)$>6;4
P&
NEJ-.+KE
J?RM?)OIU
<QKP&
N@CR"*
O0975,1;3853:5P/2LDSJBG
MRI>7:A?
*+(<@B<9ACC
<@
<
=8;A
)03/-36.(.6-2,6541. %%%'"&!!#"!!#$
'MRI+47,.0&!/
"-3)#0%)$/
(
MRI1/90246% 95%45:35856%3
476/9027% 95%45:3~4%3
3*
)$/1
+
MRIn:73% Sp:92%
CTn:73%Sp:100%
6ulio A Chalela et al The Lancet; Jan 27-Feb 2, 2007; 369, 9558
MRI#% "
!
$ulio A Chalela et al The Lancet; Jan 27-Feb 2, 2007; 369, 9558
%, 1
.&M"U$F=.&
M!+LI?J-OG
')#M/@ETG =
UCSGQLNR?&M+
@(K>S
DTPK.&M!+NCT@
V][ZWX\Y]ZK>HG
.&'U+KAS
35:8<1241;769K&M+@KAS
BM*K240KAS
%2
4/4+("
=$<>MRI=
&0:,E2;0CF9-E
)+("#=$<AMRI0
:,E2;H5E'0,87
MRI=24*03F9-E=:
,F?+("-=!<CTBD
AMRIH36E@1:,G.